<DOC>
	<DOC>NCT00984893</DOC>
	<brief_summary>The study will assess the real life effectiveness of zoledronic acid in the management of patients with osteoporosis over 4 years of treatment. Zoledronic acid will be compared to oral bisphosphonates (OBP) with respect to the change in Bone Mineral Density (BMD) and incidence of fractures.</brief_summary>
	<brief_title>Intra-venous Zoledronic Acid Once Yearly</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis, Postmenopausal</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Patient is an ambulatory female 45 years of age or older Postmenopausal women with diagnosis of osteoporosis Prescription of zoledronic acid or any OBP as per the current Canadian monograph Must provide informed consent Any prior use of iv bisphosphonates within the last 2 years Known secondary osteoporosis of any aetiology (hypogonadism in premenopausal women or premature menopause, malabsorption, chronic liver disease, inflammatory bowel disease) Metabolic bone diseases such as primary or secondary hyperparathyroidism, hypoparathyroidism, Paget's disease of bone, Fibrous dysplasia.. Noncorrected hypocalcaemia at the time of zoledronic acid infusion Creatinine clearance &lt; or = 30 ml/min Unwillingness or inability to comply with the study requirements Concurrent participation in a clinical trial of an investigational drug, or within the last 30 days Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Osteoporosis</keyword>
	<keyword>Bone Mineral density</keyword>
	<keyword>fragility fractures</keyword>
	<keyword>zoledronic acid.</keyword>
	<keyword>Treatment</keyword>
</DOC>